4.8 Article

FOG-1 and GATA-1 act sequentially to specify definitive megakaryocytic and erythroid progenitors

期刊

EMBO JOURNAL
卷 31, 期 2, 页码 351-365

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/emboj.2011.390

关键词

haematopoiesis; lineage commitment; stem cells; transcription

资金

  1. European Commission (EuroCSC STREP)
  2. Associazione Italiana per la Ricerca sul Cancro (AIRC)
  3. Swedish Research Council (HematoLinne)
  4. Medical Research Council
  5. MRC [G0900892, MC_UU_12009/5, G0801073, G0701761, G0501838] Funding Source: UKRI
  6. Medical Research Council [G0900892, G0700711B, G0701761] Funding Source: researchfish

向作者/读者索取更多资源

The transcription factors that control lineage specification of haematopoietic stem cells (HSCs) have been well described for the myeloid and lymphoid lineages, whereas transcriptional control of erythroid (E) and megakaryocytic (Mk) fate is less understood. We here use conditional removal of the GATA-1 and FOG-1 transcription factors to identify FOG-1 as required for the formation of all committed Mk- and E-lineage progenitors, whereas GATA-1 was observed to be specifically required for E-lineage commitment. FOG-1-deficient HSCs and preMegEs, the latter normally bipotent for the Mk and E lineages, underwent myeloid transcriptional reprogramming, and formed myeloid, but not erythroid and megakaryocytic cells in vitro. These results identify FOG-1 and GATA-1 as required for formation of bipotent Mk/E progenitors and their E-lineage commitment, respectively, and show that FOG-1 mediates transcriptional Mk/E programming of HSCs as well as their subsequent Mk/E-lineage commitment. Finally, C/EBPs and FOG-1 exhibited transcriptional cross-regulation in early myelo-erythroid progenitors making their functional antagonism a potential mechanism for separation of the myeloid and Mk/E lineages. The EMBO Journal (2012) 31, 351-365. doi:10.1038/emboj.2011.390; Published online 8 November 2011

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据